To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, dose escalation and cohort expansion study and conducted in
China and the United States to investigate the safety, tolerability and preliminary efficacy
of QLH11811 in advanced or metastatic NSCLC patients who have progressed after prior EGFR-TKI
treatment. The study consists of the following 2 phases: phase 1: dose escalation (1a) and
phase 2: cohort expansion (1b).